A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901
Toshiyuki Harada(Hokkaido hospital), Masaharu Nishimura(Hokkaido Institute of Public Health), Kenichiro Ito(NTT Medical Center), Tomoya Kuda(Sendai Kousei Hospital), Hiroshi Isobe, Ichiro Kinoshita(Hokkaido University), Akira Inoue(Tohoku University Hospital), Satoshi Oizumi(Hokkaido University), Hirotoshi Dosaka‐Akita(Hokkaido University Hospital), Kei Takamura(Obihiro Kosei General Hospital), Yutaka Katsuura(Fukushima Medical University Hospital), Fumihiro Hommura(Sendai Kousei Hospital), Eiki Kikuchi(Sapporo University), Shunichi Sugawara(Sendai Kousei Hospital), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Yuka Fujita, Aya Suzuki(Tokyo Medical and Dental University)
Cited by 14
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
|Nature Immunology|2012|832
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695